Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 135

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 135
---
 accumulated depreciation and amortization(18,979)(17,843)Property and equipment, net$11,069 $11,545 Depreciation and amortization expense on property and equipment was approximately $0.5 million and $1.1 million for the three and six months ended June 30, 2025 and $0.6 million and $1.2 million for the three and six months ended June 30, 2024, respectively.

Accounts Payable and Accrued LiabilitiesJune 30,2025December 31,2024(unaudited)Accounts payable$8,215 $4,587 Accrued compensation, benefits, & related accruals20,463 21,225 Accrued sales & marketing15,960 11,007 Accrued manufacturing expenses7,953 11,652 Accrued R&D expenses3,293 5,898 Operating lease liabilities, current portion (1)7,391 6,889 Accrued royalties (2)5,127 8,105 Other accrued expenses9,337 6,989 Total$77,739 $76,352 _______________________________(1)  Refer to Note 12, Leases.(2)  Refer to Note 15, Commitments and Contingencies.

20

Accrued Product Returns and RebatesJune 30,2025December 31,2024(unaudited)Accrued product rebates$134,892 $115,330 Accrued product returns46,024 53,375 Total$180,916 $168,705 

15.    Commitments and Contingencies

Product LicensesThe Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, ONAPGO, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense